Oxford Biodynamics, Holos Partner Up On Concussion
Executive Summary
Oxford Biodynamics and Holos Life Sciences are putting their heads together to develop noninvasive epigenetic biomarkers for sports-related concussions. The analysis aims to identify biomarkers that potentially could be monitored and improve athlete rehabilitation.
You may also be interested in...
OBD's Epigenetic Biomarker Tech Shows Ethnicity Issue-Free Dx Potential
Recent studies completed by epigenetic biomarker company Oxford BioDynamics have shown the company's platform technology EpiSwitch can diagnose and stage breast cancer and Amyotrophic Lateral Sclerosis (ALS). The Oxford spinout is the developer of a blood-based platform test for detecting chromosome confirmation signatures (CCSs), which overcome any ethinicity issues.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
Angle Files De Novo Submission For Parsortix System In Breast Cancer
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.